These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

338 related articles for article (PubMed ID: 9275000)

  • 1. Evolving concepts in the systemic drug therapy of breast cancer.
    Norton L
    Semin Oncol; 1997 Aug; 24(4 Suppl 10):S10-3-S10-10. PubMed ID: 9275000
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue.
    Hagemeister FB
    Cancer Chemother Pharmacol; 2002 May; 49 Suppl 1():S13-20. PubMed ID: 12042984
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Development of antituberculous drugs: current status and future prospects].
    Tomioka H; Namba K
    Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dose-dense chemotherapy for primary breast cancer.
    Kümmel S; Rezai M; Kimmig R; Schmid P
    Curr Opin Obstet Gynecol; 2007 Feb; 19(1):75-81. PubMed ID: 17218856
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antiangiogenic properties of metronomic chemotherapy in breast cancer.
    Tonini G; Schiavon G; Silletta M; Vincenzi B; Santini D
    Future Oncol; 2007 Apr; 3(2):183-90. PubMed ID: 17381418
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Modeling multi-drug chemotherapy: tailoring treatment to individuals.
    Gardner SN
    J Theor Biol; 2002 Jan; 214(2):181-207. PubMed ID: 11812172
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adjuvant therapy for breast cancer.
    Hennessy BT; Pusztai L
    Minerva Ginecol; 2005 Jun; 57(3):305-26. PubMed ID: 16166938
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of HER2 status by fluorescence in situ hybridization and immunohistochemistry to predict benefit from dose escalation of adjuvant doxorubicin-based therapy in node-positive breast cancer patients.
    Dressler LG; Berry DA; Broadwater G; Cowan D; Cox K; Griffin S; Miller A; Tse J; Novotny D; Persons DL; Barcos M; Henderson IC; Liu ET; Thor A; Budman D; Muss H; Norton L; Hayes DF
    J Clin Oncol; 2005 Jul; 23(19):4287-97. PubMed ID: 15994142
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Medical therapy of advanced malignant epithelial tumours of the ovary.
    Colombo N; Parma G; Bocciolone L; Franchi D; Sideri M; Maggioni A
    Forum (Genova); 2000; 10(4):323-32. PubMed ID: 11535983
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741.
    Citron ML; Berry DA; Cirrincione C; Hudis C; Winer EP; Gradishar WJ; Davidson NE; Martino S; Livingston R; Ingle JN; Perez EA; Carpenter J; Hurd D; Holland JF; Smith BL; Sartor CI; Leung EH; Abrams J; Schilsky RL; Muss HB; Norton L
    J Clin Oncol; 2003 Apr; 21(8):1431-9. PubMed ID: 12668651
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dose and schedule as determinants of outcomes in chemotherapy for breast cancer.
    Budman DR
    Semin Oncol; 2004 Dec; 31(6 Suppl 15):3-9. PubMed ID: 15726532
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Conventional adjuvant chemotherapy versus single-cycle, autograft-supported, high-dose, late-intensification chemotherapy in high-risk breast cancer patients: a randomized trial.
    Leonard RC; Lind M; Twelves C; Coleman R; van Belle S; Wilson C; Ledermann J; Kennedy I; Barrett-Lee P; Perren T; Verrill M; Cameron D; Foster E; Yellowlees A; Crown J;
    J Natl Cancer Inst; 2004 Jul; 96(14):1076-83. PubMed ID: 15265969
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Preoperative therapy in invasive breast cancer: pathologic assessment and systemic therapy issues in operable disease.
    Gralow JR; Burstein HJ; Wood W; Hortobagyi GN; Gianni L; von Minckwitz G; Buzdar AU; Smith IE; Symmans WF; Singh B; Winer EP
    J Clin Oncol; 2008 Feb; 26(5):814-9. PubMed ID: 18258991
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Endocrine therapy and other targeted therapies for metastatic breast cancer.
    Hussain SA; Palmer DH; Moon S; Rea DW
    Expert Rev Anticancer Ther; 2004 Dec; 4(6):1179-95. PubMed ID: 15606341
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Drug development for cancer chemoprevention: focus on molecular targets.
    Johnson KA; Brown PH
    Semin Oncol; 2010 Aug; 37(4):345-58. PubMed ID: 20816505
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Concepts and clinical trials of dose-dense chemotherapy for breast cancer .
    Orzano JA; Swain SM
    Clin Breast Cancer; 2005 Dec; 6(5):402-11. PubMed ID: 16381623
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adjuvant chemotherapy in early-stage breast cancer: what, when, and for whom?
    Kelly CM; Hortobagyi GN
    Surg Oncol Clin N Am; 2010 Jul; 19(3):649-68. PubMed ID: 20620933
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Proceedings of the First Global Workshop on Breast Cancer: pathways to the evaluation and clinical development of novel agents for breast cancer.
    Albain KS; Carey L; Gradishar WJ; Gralow JR; Lipton A; Rugo H; Tripathy D; Peck S; Abair T; Pegram M
    Clin Breast Cancer; 2010 Dec; 10(6):421-39. PubMed ID: 21147685
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Therapeutic consequences of molecular biology advances in oncology].
    Bauvet F; Awada A; Gil T; Hendlisz A
    Bull Cancer; 2009 Jan; 96(1):59-71. PubMed ID: 19211361
    [TBL] [Abstract][Full Text] [Related]  

  • 20. First-line chemotherapy with or without biologic agents for metastatic breast cancer.
    Andreetta C; Minisini AM; Miscoria M; Puglisi F
    Crit Rev Oncol Hematol; 2010 Nov; 76(2):99-111. PubMed ID: 20097088
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.